1. Home
  2. Products
  3. Customized ADCs
  4. ERBB2
  5. Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC

Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC (CAT#: ADC-W-572)

This ADC product is comprised of a Fab of anti-ERBB2 monoclonal antibody (Trastuzumab) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Similar to
  • T-SPP-DM1
  • Name
  • ERBB2
  • Alternative Names
  • ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 1
  • Target Entrez Gene ID
  • 2064
  • Overview
  • This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
  • Overview
  • Humanized Anti-ERBB2 lgG1 Antibody, Trastuzumab
  • Generic name
  • Trastuzumab
  • Species Reactivity
  • Human
  • Name
  • SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
  • Description
  • Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
  • Name
  • DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
  • Description
  • Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
    macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-572. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-1110 Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-1112 Anti-ERBB2 (Pertuzumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-2597 Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1111 Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1115 Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
CAT# Product Name Linker Payload
ADC-W-317 Anti-MUC1 (clone huC242)-SPP-DM1 ADC SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-460 Anti-NCAM1 (clone huN901)-SPP-DM1 ADC SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-613 Anti-CD19 (B496)-SPP-DM1 ADC SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-621 Anti-CR2 (THB-5)-SPP-DM1 ADC SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-230 Anti-MUC1 ( huC242)-SPP-DM1 ADC SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-460 Anti-NCAM1 (clone huN901)-SPP-DM1 ADC SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-487 Anti-CD70-MCC-DM1 ADC MCC (Maleimidomethyl cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-495 Anti-EGFR (J2898A)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-054 Protein A-MCC-DM1 ADC MCC (Maleimidomethyl cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-582 Anti-ERBB2-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.